Efficacy and safety of tyrosine kinase inhibitors combined with sintilimab and transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma: a pooled analysis.

ABSTRACT:

Background

Trials on tyrosine kinase inhibitors combined with sintilimab and transarterial chemoembolization (TKIs-Sin-TACE) for the treatment of unresectable hepatocellular carcinoma (HCC) are ongoing and show promising results. However, the number of participants recruited so far has been relatively limited. This pooled analysis aims to evaluate the efficacy and safety of TKIs-Sin-TACE in patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC.

Methods

To obtain potentially eligible studies, databases such as PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched up to October 1, 2024. The Methodological Index for Non-Randomized Studies (MINORS) was used to evaluate literature quality and the levels of bias. A random-effects model w

SUBMITTER: Lu GL 

PROVIDER: S-EPMC12780591 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature